Serum total bilirubin > 1.5 mg/dL or > 3 × ULN for patients with hereditary benign hyperbilirubinemia
Serum total bilirubin > 1.5 mg/dL or > 3 × ULN for patients with hereditary benign hyperbilirubinemia
Serum total bilirubin > 1.5 mg/dL or > 3 x ULN for patients with hereditary benign hyperbilirubinemia
Hepatic: < 2 x ULN total serum bilirubin, unless there is congenital benign hyperbilirubinemia.
Bilirubin < 1.5 mg/dL (unless benign congenital hyperbilirubinemia).
Hepatic impairment, defined as total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (patients with benign hyperbilirubinemia [e.g., Gilbert’s syndrome] are eligible) or
Hepatic impairment, defined as total bilirubin > 1.5 x institutional ULN (patients with benign hyperbilirubinemia [e.g., Gilbert’s syndrome] are eligible) or
< 2.0 x ULN serum bilirubin, unless there is congenital benign hyperbilirubinemia
Total bilirubin =< 2 X ULN (exceptions may apply to benign non-malignant indirect hyperbilirubinemia such as Gilbert syndrome)
=< 1.5 total serum bilirubin, unless there is congenital benign hyperbilirubinemia or if the hyperbilirubinemia is directly caused by the disease in which the patient is receiving a transplant (e.g. AML chloroma obstructing the biliary tree); patients with higher bilirubin levels due to causes other than active liver disease are also eligible with principal investigator (PI) approval e.g. patients with paroxysmal nocturnal hemoglobinuria (PNH), Gilbert's disease or other hemolytic disorders
Alanine aminotransferase (ALT) < 3 x upper limit of normal unless benign congenital hyperbilirubinemia
Obtained within 14 days (or as stipulated) prior to study drug (treatment) administration: total bilirubin ? 2.0 mg/dL or > 3.0 x ULN for subjects with hereditary benign hyperbilirubinemia
Total bilirubin > 1.5 x institutional upper limit of normal (ULN) (patients with benign hyperbilirubinemia [e.g., Gilbert’s syndrome] are eligible), within 21 days of initiation of protocol therapy
Bilirubin > 1.5 x institutional upper limit of normal (ULN) (patients with benign hyperbilirubinemia [e.g., Gilbert's syndrome] are eligible) or
Bilirubin > 1.5 x institutional upper limit of normal (ULN); patients with benign hyperbilirubinemia (e.g., Gilbert’s syndrome) are eligible
Total serum bilirubin < 1.5, unless there is congenital benign hyperbilirubinemia
Total bilirubin =< 2 x upper limit of normal (ULN) (exceptions may apply to benign non-malignant indirect hyperbilirubinemia such as Gilbert syndrome)
Total bilirubin =< 1.5 mg/dL (unless benign congenital elevated bilirubin)
Total bilirubin less than or equal to 2 x upper limit of normal (ULN) (exceptions may apply to benign non-malignant indirect hyperbilirubinemia such as Gilbert syndrome)
Hepatic: < 1.5 total serum bilirubin, unless there is congenital benign hyperbilirubinemia
Total bilirubin =< 2.0 (exceptions may apply to benign non-malignant indirect hyperbilirubinemia such as Gilbert syndrome)
Hepatic: < 1.5 total serum bilirubin, unless there is congenital benign hyperbilirubinemia
Bilirubin =< 2 mg/dL (exceptions may apply to benign non-malignant indirect hyperbilirubinemia such as Gilbert syndrome)
Total serum bilirubin < 1.5 x ULN, unless there is congenital benign hyperbilirubinemia
Serum total bilirubin ? 2.0 mg/dL (34.2 ?mol/L); or > 3.0 × upper limit of normal (ULN) for subjects with hereditary benign hyperbilirubinemia
Serum total bilirubin > 1.5 mg/dL or > 3 × ULN for patients with hereditary benign hyperbilirubinemia
< 3 x ULN alanine aminotransferase (ALT), unless there is congenital benign hyperbilirubinemia
< 1.5 total serum bilirubin, unless there is congenital benign hyperbilirubinemia
Hepatic: < 1.5 total serum bilirubin, unless there is congenital benign hyperbilirubinemia
